Loading...

The current price of VYNE is 0.37 USD — it has decreased -1.6 % in the last trading day.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Wall Street analysts forecast VYNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYNE is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Vyne Therapeutics Inc revenue for the last quarter amounts to 169.00K USD, increased 39.67 % YoY.
Vyne Therapeutics Inc. EPS for the last quarter amounts to -0.17 USD, decreased -41.38 % YoY.
Vyne Therapeutics Inc (VYNE) has 13 emplpoyees as of December 15 2025.
Today VYNE has the market capitalization of 12.50M USD.